Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $278,000.

  • Fulcrum Therapeutics' Capital Expenditures fell 38.16% to $94,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $409,000, marking a year-over-year increase of 27.02%. This contributed to the annual value of $278,000 for FY2024, which is 45.28% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Capital Expenditures of $278,000 as of FY2024, which was down 45.28% from $508,000 recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Capital Expenditures peaked at $2.0 million during FY2022, and registered a low of $278,000 during FY2024.
  • Its 3-year average for Capital Expenditures is $916,333, with a median of $508,000 in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 57.33% in 2020, then plummeted by 74.12% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Capital Expenditures (Yearly) stood at $1.3 million in 2020, then climbed by 27.65% to $1.7 million in 2021, then increased by 14.59% to $2.0 million in 2022, then crashed by 74.12% to $508,000 in 2023, then tumbled by 45.28% to $278,000 in 2024.